Purpose: De-regulation of microRNA (miRNA) has been extensively investigated in both Hodgkin (HL) and non-Hodgkin lymphomas (NHL), however, little is known about the roles of miRNAs in T-cell lymphoblastic lymphoma (T-LBL). The aim of the present study was to investigate the potential roles of miR-374b in the development and treatment of T-LBL.
Introduction microRNAs (miRNAs) belong to a class of phylogenetically conserved noncoding
RNAs that suppress protein expression through base pairing with 3'-untraslated regions (3'-UTR) of target genes (1) (2) . Emerging evidence suggests that miRNAs are aberrantly expressed during the development and progression of a variety of human cancers, including leukemia and lymphoma (3) (4) (5) .
Lymphoblastic lymphoma (LBL) is a rare heterogeneous group of immature B cells committed to the B-cell lineage (B-LBL) or T-cell lineage (T-LBL) whose incidence
accounts for approximately 1-2% of non-Hodgkin's lymphomas worldwide (6) (7) .
T-LBL comprises about 90% of all LBL that are typically seen in late childhood, adolescence, and young adulthood with a male predominance (8) (9) . T-LBL is a chemotherapy-sensitive disease with a 75%-85% event-free survival rate using current treatment regiments. However, because of frequent relapse, 5-year overall survival is poor (30%-50%) (10) (11) . Furthermore, 5-year survival in relapsed patients is only 10%-15% (12) (13) . Therefore, reliable markers to predict T-LBL relapse and prognosis are highly desired to optimize therapeutic strategies and improve clinical outcomes. Deregulation of miRNAs has been extensively investigated in both
Hodgkin and non-Hodgkin lymphomas (4, 14) . Higher levels of miR-155, miR-21, and miR-221 predict a poor prognosis for diffuse large B-cell lymphoma (15) (16) (17) . Reduced expression of miR-143 and miR-145 has also been documented in B-cell malignancies, and re-expression of these miRNAs in a Burkitt lymphoma cell line demonstrated a dose-dependent growth inhibitory effect (18) . These findings suggest
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Author Manuscript Published OnlineFirst on June 22, 2015; DOI: 10.1158/1078-0432.CCR-14-2947 6 the involvement of miRNAs in the pathogenesis of lymphoma, and miRNAs can be effective biomarkers to predict outcomes and improve therapy responses of patients with lymphoma. Most recently, K. Basso has reported the first characterization of childhood T-LBL by miRNA expression profiling and identified some miRNAs that are de-regulated in T-LBL (19) . However, little is known about miRNAs in the development and treatment of T-LBL. Therefore, extensive investigations on the functions of miRNAs that are deregulated in T-LBL are required.
In this study, for the first time, we report that the down-regulation of miR-374b is significantly associated with the survival of T-LBL patients. Moreover, in vitro and in vivo studies demonstrate that ectopic restoration of miR-374b promotes apoptosis and suppresses proliferation T-NHL cell through repressing AKT signaling pathway. Our findings highlight the functions and roles of miRNAs in T-LBL, and suggest miR-374b could be used as a novel prognostic marker and potential therapeutic target for T-LBL patients.
Materials and Methods
Tissue specimens and cell cultures
T-LBL tissue samples were obtained with informed consent under Institutional
Review Board-approved protocols. The samples were collected at the Cancer Center, Sun Yat-Sen University (Guangzhou, China). The T-LBL cases selected were based on clear pathological diagnosis and follow-up data, and were from patients that had not
Research. Two T-cell lines (Jurkat and SUP-T1) were obtained from ATCC (American Type Culture Collection). Cells were cultured less than three months after resuscitation and were maintained in RPMI 1640 media (Gibco Laboratories, Buffalo, Grand Island, NY, USA) with 10% (vol/vol) fetal bovine serum (Gibco Laboratories) at 37°C in a 5% CO 2 incubator. Cells were authenticated by short tandem repeat (STR) fingerprinting at Medicine Lab of Forensic Medicine Department of Sun Yat-sen University (Guanzhou, China).
MicroRCURY LNA array analysis
Total RNA was extracted from five pairs of T-LBL and normal infantile thymus using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA). Microarray chip analysis was performed and analyzed by Applied Biosystems Human MicroRNA Cards (A and B Cards, respectively, Applied Biosystems, Vedbaek, Denmark). These 2 panels are designed with 768 unique assays of human miRNAs (The data have been deposited in the Gene Expression Omnibus database under accession code GPL17797 ) Among the 768 human miRNA probes, the microarray detected 367
Research. RNA quality was determined using the Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). All the samples had an RNA integrity number greater than 7.0. The fold change was calculated by comparing the expression of miRNA in the T-LBL tumor pool and the infantile thymus in a log 2 format.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from formalin fixed and paraffin embedded tissues (FFPETs) Receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff score for tumor "high expression" using the 0, 1-criterion (20) . At the miR-374b expression RQ, the sensitivity and specificity for each outcome under study was plotted, thus generating various ROC curves. The score was selected as the cutoff value, which was closest to the point with both maximum sensitivity and specificity (21) .
Plasmid construction, lentivirus production and transduction
The pre-miR-374b precursor, anti-miR-374b (with sequence that was complementary to mature miR-374b) and the coding sequences of WNT16 and AKT1 constructs were 
MTT assay
Cell viability was measured by a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl Experiments were performed in triplicate.
In vivo experiments
For in vivo study, 2×10 6 
Luciferase reporter assay
The putative miR-374b binding site at the 3′-UTR of WNT16 and AKT1 mRNAs was cloned downstream of the cytomegalovirus (CMV) promoter in a pMIR-REPORT vector (Ambion, Carlsbad, CA, USA). Two mutant constructs were generated by either deletion or mutation.
The firefly luciferase construct was cotransfected with a control Renilla luciferase vector into Jurkat and SUP-T1 cells in the presence of either miR-374b or miR-control. A dual luciferase assay (Promega) was performed 48 h after transfection.
The experiments were performed independently in triplicate.
Western blot analysis
Western blot was performed according to the standard protocol with antibodies to PARP, Caspase3, cleaved-Caspase3, AKT, AKT1, p-AKT, mTOR, p-mTOR, GSK3β, p-GSK3β, BAD, p-BAD, FOXO1/3 and p-FOXO1/3 (Cell Signaling Technology, Danvers, MA, USA). Anti-Wnt16 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, CA, USA). GAPDH (Santa Cruz Biotechnology) was used as a normalized control. All protein bands were detected using a SuperSignal West Pico Chemiluminescent Substrate (Pierce). The lanes of Western Blotting were scanned and band densities quantified using the Quantity-One 
H&E staining analysis and IHC
H&E staining analysis was performed as previously described (22) . IHC staining was performed on 5-μm tissue sections rehydrated through graded alcohols. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15 min. 
Immunohistochemistry evaluation
The expression of AKT1 and Wnt16 was assessed by three independent pathologists The survival curves were plotted by Kaplan-Meier analysis. Differences were considered significant when the p value was less than 0.05.
Results

MiR-374b is frequently down regulated in T-LBL
To investigate the roles of miRNAs in T-LBL, miRCURY LNA array (Exiqon) containing 750 human miRNAs was performed to compare the miRNA expression Table 2 ). The relative expression of these miRNAs is presented as a heat map ( Figure 1A ). miR-374b, which showed lower expression in all five primary T-LBL samples than in normal infantile thymus, was chosen for further study. Quantitative PCR was performed to confirm the expression of miR-374b in 30 infantile thymus and 58 primary T-LBL samples. Consistent with the array, miR-374b was strongly downregulated in these T-LBL samples ( Figure 1B ).
Down regulation of miR-374b is associated with poor prognosis of T-LBL
To address the clinical significance of the down regulation of miR-374b in T-LBL, the correlation of miR-374b with clinical-pathological features from these patients was studied. We first subjected the value of miR-374b expression in the 58 cases of T-LBL tissues to ROC curve analysis with respect to each clinicopathologic feature. The corresponding area under the curve and cutoff scores for high expression of miR-374b are shown in Supplementary Figure 1 Table 4 ). Additionally, Kaplan-Meier analysis revealed lower miR-374b levels were associated with poorer overall survival and a higher risk of recurrence in the T-LBL cohort (p≤0.05) (Figure 1C, D) . These results suggested that the down regulation of miR-374b might play an important role in the development and progression of T-LBL.
MiR-374b suppresses tumor cell growth
To explore the potential tumor-suppressive role of miR-374b in T-LBL, the miR-374b precursor was cloned and stably transfected into Jurkat and SUP-T1 cell lines. The expression of mature miR-374b was confirmed by quantitative PCR (Figure 2A ).
MTT assay showed that miR-374b inhibited cell growth compared with empty vector-transfected control cells ( Figure 2B ). Furthermore, we examined the anti-tumor effect of miR-374b on T-LBL xenografts in vivo. SUP-T1-374b cells and vector control SUP-T1 cells were inoculated into female athymic nude mice. Consistent with the in vitro study results, miR-374b inhibited tumor formation in vivo ( Figure 2C ). In addition, immunohistochemical staining of Ki67 was performed to detect proliferating cells. As expected, less Ki67 expression was detected in SUP-T1-374b cells than in SUP-T1-vector control cells ( Figure 2D ). Moreover, loss of function studies revealed that depletion of miR-374b promoted cell proliferation in both Jurkat and SUP-T1 cells ( Supplementary Figure 2A-B) . The effect of miR-374b on Jurkat xenografts was also studied. In consistent with the in vitro results, inhibition of miR-374b
Research. 
promoted tumor formation in vivo. In contrast, overexpression of miR-374b suppressed tumor growth in Jurkat xenografts (Supplemental Figure 2C) . These results implied that miR-374b has a strong ability to suppress tumor cell growth.
MiR-374b promotes apoptosis of T-LBL cells
To determine whether miR-374b has a pro-apoptotic effect on T-LBL cells, Annexin V/PI staining cell apoptosis assay was performed. Flow cytometry analysis indicated that miR-374b dramatically promoted tumor cell apoptosis in Jurkat and SUP-T1 cells compared with the vector-transfected control cells under normal conditions (p<0.05, Figure 3A ). Additionally, we examined the effect of miR-374b on serum-deprived and chemotherapy-induced apoptosis using the same cell lines. Compared with negative controls, the enhanced expression of miR-374b significantly increased the apoptotic rate of cells cultured without serum for 36h (p<0.01, Figure 3A ), or exposed to doxorubicin, a major drug used for chemotherapy of T-LBL, for 24h at the indicated concentration (p<0.01, Figure 3A) . In contrast, depletion of miR-374b inhibited apoptosis in both Jurkat and SUP-T1 cells (Supplementary Figure 2D) . Moreover, western blot analysis suggested a significant decrease in levels of pro-caspase-3, increased levels of cleaved caspase-3, and cleaved PARP in miR-374b restored cells treated with either serum deprivation or doxorubicin ( Figure 3B ). Together, these results demonstrate that miR-374b promotes the apoptosis of T-LBL cells.
Wnt16 and AKT1 are direct targets of miR-374b
Research. As miR-374b suppressed cell growth and enhanced cell apoptosis in T-LBL, we explored the molecular mechanisms responsible for the effect of miR-374b. By searching TargetScan, pictar and miRanda, we compiled all the predicted genes for functional clustering analysis classified by DAVID 6.7, Kegg and Panther databases (23) . Based on a previously used method (24) , Wnt16 and AKT1 were identified as targets of miR-374b, and which contained a putative target sequence ( Figure 4A ). To validate whether Wnt16 and AKT1 were the direct downstream targets of miR-374b, fragments of the 3'-UTR of Wnt16 and AKT1 ( Figure 4A) containing the potential miR-374b binding site were cloned into a vector with the firefly luciferase reporter gene. Luciferase activity was reduced by approximately 55%
and 43% compared with the control but not that of the mutant reporter ( Figure 4B ).
Furthermore, reverse transcription-PCR (RT-PCR) and Western blotting were used to
test whether the expression of Wnt16 and AKT1 was repressed by miR-374b. The WNT16 gene spans four exons with alternative exons 1a and 1b. Each exon 1 is associated with a unique promoter allowing the transcription of two different mRNA isoforms: Wnt16a and Wnt16b (25) . However, no expression of Wnt16a was detected in either Jurkat or SUP-T1 cells using specific primers ( Figure 4C ). We concluded that the isoform detected by RT-PCR and Western blot was Wnt16b in these cell lines.
Furthermore, the result showed that miR-374b down regulated the expression of Wnt16 and AKT1 at the mRNA ( Figure 4C ) and protein level ( Figure 4D ). Moreover, both the anti-growth and apoptosis-promoting effects of miR-374b were partly rescued when Wnt16b or AKT1 was replenished in SUP-T1-374b cells respectively
Research. Figure 3A-C) . A correlation between miR-374b levels and the expression of Wnt16 and AKT1was further examined in T-LBL tissues by immunohistochemistry, and miR-374b was determined by qPCR in the same set of specimens shown in Figure 1 . miR-374b levels were inversely correlated with Wnt16 and AKT1 expression ( Figure 5A, B) . Furthermore, higher Wnt16 and AKT1 levels were also associated with poorer overall survival and a higher risk of recurrence in the T-LBL cohort (p≤0.05, Figure 5C, D) , which is consistent with that of lower miR-374b levels in T-LBL specimens.
These data suggest that miR-374b may negatively regulate the expression of Wnt16 and AKT1 by directly targeting the 3'-UTR of their mRNAs.
MiR-374b suppresses cell growth and enhances cell apoptosis through inhibiting the AKT signaling pathway
Given that both Wnt16 and AKT1 play crucial roles in the AKT signaling pathway (26) (27) , the roles of miR-374b in the activation of AKT were investigated.
Interestingly, the expression of phosphorylated AKT and total AKT was dramatically inhibitor (40 µM AKT inhibitor V) that it sufficiently block AKT activation, the effect of miR-374b disappeared almost completely (Figure 6B-D) . Interesting, the additive effect was well presented when miR-374b combined with lower dose of AKT inhibitor V (20 µM) (Supplementary Figure 4) . These results further confirm that miR-374b suppresses cell growth and enhances cell apoptosis through inhibiting the AKT signaling pathway.
Discussion
MiR-374b was significantly down-regulated in the T-LBL tissues examined in this study, and was involved in multiple physical functions and diseases, such as lipid metabolism, renal Ca 2+ homeostasis and vascular permeability in injury (28) (29) (30) (31) .
However, little is known about the roles and mechanisms of miR-374b in the human cancer process. In the present study, we demonstrated that down regulation of miR-374b was significantly associated with a high risk of relapse and worse overall survival in T-LBL patients. Furthermore, our in vitro and in vivo studies showed that ectopic restoration of miR-374b suppressed cell proliferation and tumorigenicity and (32) (33) (34) . In the present study, we characterized AKT1 as a functional target of miR-374b. This suggested that the AKT might be a downstream signaling molecule of miR-374b and play a pivotal role. Wnt16 was another gene we identified as a target of miR-374b for the first time. The WNT pathway is a powerful signaling pathway that is widely involved in developmental processes and oncogenesis. Wnt signaling is very complicated and 19 Wnt proteins have been identified, including Wnt16 (35) (36) , which has two isoforms, Wnt16a and Wnt16b. Only Wnt16b expression was detected by RT-PCR in the T-LBL cells. A similar result was observed in MRC5 human fibroblasts (26) . Wnt16b was initially described as an oncogene that activated β-catenin in pre-B acute lymphoblastoid leukemia or enhanced the survival of cancer cells with or without cytotoxic therapy via a β-catenin-independent non-canonical WNT transduction pathway (37) (38) . Furthermore, Binet et al. reported Wnt16b was identified as a new marker of senescence and over-expression of Wnt16b activated the PI3K/AKT pathway (26) . Consistent with previous reports, overexpression of Wnt16b in our SUP-T1-374b cells partly rescued the levels of phosphor-AKT which was suppressed by miR-374b (Supplementary Figure 3A) . Up-regulation of Wnt16b in both Jurkat and SUP-T1 blank cells enhanced the activation of AKT (Supplementary Figure 5A) . Moreover, the anti-growth and apoptosis-promoting effects of miR-374b
were only slightly rescued when β-catenin was up-regulated in SUP-T1-374b cells (Supplementary Figure 5B) . In addition, XAV-939, a Wnt inhibitor that augments β-catenin degradation though its stabilization of AXIN (39) , at 2 uM was applied to block the Wnt/β-catenin signaling pathway in our T-LBL cells. Our results showed
Research. that there was a marked addictive effect when using XAV-939 in miR-374b-over-espression T-LBL cells (Supplementary Figure 5C-D) . These results further supported that inhibition of AKT activation which induced by suppressing a β-catenin-independent effect of Wnt16b may be a mechanism by which miR-374b suppresses proliferation and promotes apoptosis in T-LBL cells. Based on these findings, we hypothesized whether reintroduction of miR-374b could regulate the PI3K/AKT pathway. Our results clearly showed that phosphor-AKT levels were markedly down regulated in miR-374b-restored T-LBL cells. To our knowledge, activated AKT promotes proliferation and decrease of apoptosis in cancer cells by phosphorylating a large number of downstream substrates containing the consensus sequence RXRXXS/T, such as mTOR, GSK3β, caspase cascade, and FoxO family members (40) (41) (42) . Our results also showed that AKT/mTOR, AKT/BAD and AKT/FoxO signaling were all inhibited followed by deregulation of phosphor-AKT in the miR-374b over-expressing cells. These AKT-mediated signaling pathways play a profound role in multiple critical cellular processes, including cell proliferation and apoptosis (43) (44) . These findings further support the idea that miR-374b functions mainly through the AKT signaling pathway. However, GSK3, another important AKT-phosphorylated substrate (45) , was not affected by miR-374b restoration. Further studies are required to elucidate the complex interactions between miR-374b and the AKT signaling pathway. PTEN has been showed to be a tumor suppressor gene that inhibits the PI3K/AKT signaling pathway and is either deleted or mutated in high percentage of human tumors (46) (47) (48) . The relationship between miR-374b and PTEN was Figure 6) .
These results suggest that miR-374b and PTEN might inhibit the AKT signaling pathway by different mechanisms.
He et al. reported that miR-374b was down regulated in prostate cancer tissue, and was identified as an independent predictor of biochemical recurrence-free survival (31) .
Our result also clearly showed that miR-374b was frequently down regulated in T-LBL tissues. However, a most recently study showed that the expression levels of miR-374b was not different between HCC and non-cancerous liver tissues (49) ,
suggesting that the functions of miR-374b in tumorigenesis are complicated and may be tumor-type-specific. In the cohorts of our T-LBL patients, low expression of miR-374b was found to correlate positively with a high risk of relapse in T-LBL patients, and miR-374b down regulation was a strong and independent predictor for poor survival. In our clinical T-LBL tissues, we found that the expression levels of both AKT1 and Wnt16 were inversely correlated with miR-374b levels. Therefore, miR-374b might be a promising biomarker for predicting relapse and survival of 
